Answers are grounded in this paper and cite their sources.
To the Editor: In the SYMMETRY trial involving patients with metabolic dysfunction–associated steatohepatitis (MASH) with biopsy-confirmed compensated cirrhosis, Noureddin et al. (June 26 issue) 1 conclude that efruxifermin does not significantly reduce liver fibrosis at 36 weeks. However, this conclusion overlooks a critical confounder: certain patients may have used medications for concomitant hypertension, type 2 diabetes, or both. Many such drugs, including some specific sulfonylureas, statins, and antihypertensive agents, are metabolized by the liver and may induce hepatic stress or have toxic effects that could worsen fibrosis or mask therapeutic effects. 2,3 Medication regimens were not systematically recorded in the trial, and drug . . .
No takes yet. Share an insight, caveat, or question.
Shringarpure et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: